FastingPhase 1NCT06199791
Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions
A Phase 1 study testing Lamotrigine 100 MG in people with Fasting, run by Desitin Arzneimittel GmbH at 1 site in Canada.
Trial summary
To assess the bioequivalence of lamotrigine from Lamotrigin Desitin 100 mg tablets and Lamictal 100 mg Tablet. Read more about this study
- Who is it for?
- Ages 18 to 65 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Fasting
- What is being tested?
- Lamotrigine 100 MG
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteCanada
- Study dates
- 3 Apr 2023to 14 Jun 2023
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy, non-smoking (for at least 6 months prior to first drug administration), male volunteers 18 to 65 years of age inclusive.
- BMI that was within 18.5-30.0 kg/m², inclusive.
- Healthy, according to the medical history, ECG, vital signs, laboratory results and physical examination as determined by the PI/Sub-Investigator.
- QTcB interval < 440 milliseconds for males, unless deemed otherwise by the PI/Sub- Investigator.
- Systolic blood pressure between 95-140 mmHg, inclusive, and diastolic blood pressure between 55-90 mmHg, inclusive, and heart rate between 50-100 bpm, inclusive, unless deemed otherwise by the PI/Sub-Investigator.
- Clinical laboratory values within BPSI's most recent acceptable laboratory test range, and/or values were deemed by the PI/Sub-Investigator as "Not Clinically Significant".
Show all 16Show fewer
- Ability to comprehend and be informed of the nature of the study, as assessed by BPSI staff. Capable of giving written informed consent prior to any study-related procedure.
- Must have been able to communicate effectively with clinic staff.
- Ability to fast for at least 14 hours and consume standard meals.
- Availability to volunteer for the entire study duration and was willing to adhere to all protocol requirements.
- Agreed not to have a tattoo or body piercing until the end of the study.
- Agreed not to receive the COVID-19 vaccination from 7 days prior to the first study drug dose until 7 days after the last study drug administration in the study.
- Agreed to limit exposure to sunlight and UV light by wearing protective clothing and using a sunscreen with a high protection factor during the study.
- Agreed not to drive or operate heavy machinery if feeling dizzy or drowsy following study drug administration until full mental alertness was regained.
- Males who were able to father children agreed to use medically acceptable methods of contraception during the study and for 30 days after the last study drug administration.
- Medically acceptable methods of contraception included using a condom with a female partner of child-bearing potential who was using oral contraceptives, hormonal patch, implant or injection, intrauterine device, or diaphragm with spermicide. Abstinence as a method of contraception was acceptable if it was in line with the preferred and usual lifestyle of the study participant. If a subject's partner became pregnant during his participation in the study and for 30 days after he had completed his last study drug administration, he must have informed BPSI staff immediately.
Who cannot join
- Known history or presence of any clinically significant hepatic, renal/genitourinary, gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological or hematological disease or condition unless determined as not clinically significant by the PI/Sub-Investigator.
- Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g., chronic diarrhea, inflammatory bowel disease), unresolved gastrointestinal symptoms (e.g., diarrhea, vomiting), or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug experienced within 7 days prior to first study drug administration, as determined by the PI/Sub-Investigator.
- Presence of any clinically significant illness within 30 days prior to first dosing, as determined by the PI/Sub-Investigator.
- Presence of any significant physical or organ abnormality as determined by the PI/Sub-Investigator.
- A positive test result for any of the following: HIV, Hepatitis B surface antigen, Hepatitis C, drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), alcohol breath test and cotinine.
- Known history or presence of:
Show all 36Show fewer
- Alcohol abuse or dependence within one year prior to first study drug administration.
- Drug abuse or dependence within the last 2 years.
- Prior history or family history of hypersensitivity or idiosyncratic reaction to any drug including but not limited to Lamotrigine, its excipients, and/or related substances;
- Suicidal ideation or suicidal behavior, as assessed by the Columbia Suicide Severity Rating Scale (baseline version) - Appendix B (Refer to Appendix 16.1.1)
- Prior history or family history of allergic drug rash to any drug including but not limited to lamotrigine, its inactive ingredients and/or any other related marketed drugs, including Lamictal XR and Lamictal.
- Prior history or family history of Stevens-Johnson Syndrome (SJS);
- Lactose intolerance;
- Food allergies;
- Presence of any dietary restrictions unless deemed by the PI/Sub-I as "Not Clinically Significant".
- Severe allergic reactions (e.g., anaphylactic reactions, angioedema).
- Intolerance to and/or difficulty with blood sampling through venipuncture.
- Abnormal diet patterns (for any reason) during the four weeks preceding the study, including fasting, high protein diets etc.
- Individuals who had donated, in the days prior to first study drug administration:
- 50-499 mL of blood in the previous 30 days;
- 500 mL or more in the previous 56 days.
- Donated plasma by plasmapheresis within 7 days prior to first study drug administration.
- Individuals who had participated in another clinical trial or who received an investigational drug within 30 days prior to first study drug administration.
- Use of any enzyme-modifying drugs and/or other products, including strong inhibitors of cytochrome P450 (CYP) enzymes (e.g., cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (e.g., barbiturates, carbamazepine, glucocorticoids, phenytoin, St. John´s Wort, and rifampicin) in the previous 30 days before first study drug administration.
- Used any prescription medication within 14 days prior to first study drug administration (except for spermicidal/barrier contraceptive products).
- Used of any over-the-counter medications (including oral multivitamins, herbal and/or dietary supplements) within 14 days prior to first study drug administration (except for spermicidal/barrier contraceptive products).
- Used Acetaminophen (Paracetamol) during the study.
- Consumed food or beverages containing grapefruit and/or pomelo within 10 days prior to first study drug administration.
- Consumed food or beverages containing caffeine/methylxanthines, poppy seeds and/or alcohol within 48 hours before dosing in each study period.
- Individuals who had undergone any major surgery within 6 months prior to the start of the study, unless deemed otherwise by PI/Sub-Investigator.
- Difficulty with swallowing whole tablet.
- Unable or unwilling to provide informed consent.
- Had a tattoo or body piercing within 30 days prior to first study drug administration.
- Recent history (within 8 weeks prior to screening) of travel to or emigration from any country with high incidence for tuberculosis.
- History or presence of tuberculosis or a positive QUANTIFERON blood test/Tuberculin Skin Test result.
- A subject who, in the opinion of the investigator or designee, is considered unsuitable or unlikely to comply with the study protocol for any reason.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Single-Dose, Randomized, Two-Way Crossover, Bioequivalence of Lamotrigine 100 mg Tablet (Desitin Arzneimittel GmbH, Germany) and Lamictal 100 mg Tablet (GlaxoSmithKline GmbH & Co. KG, Germany) in Healthy, Male Volunteers, Fasting
To assess the bioequivalence of lamotrigine from Lamotrigin Desitin 100 mg tablets and Lamictal 100 mg Tablet.
Read the detailed description
In the pivotal study bioequivalence of Lamotrigin Desitin 100 mg tablets and Lamictal 100 mg tablet in healthy, male volunteers should be proven.
The drug products were studied using a crossover design with 24 healthy, non-smoking, male volunteers being administered an oral dose of 1 × 100 mg tablet under fasting conditions.
- Conditions
- Fasting
- Being tested
- Lamotrigine 100 MG
- Medical subject headings
- Fasting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lamotrigine 100 MGDrug
Also called Lamotrigin Desitin 100 mg
tablets
| Study group | Role | What they receive |
|---|---|---|
| Lamotrigine 100 mg oral tablet | Experimental | Test Receives: Drug: Lamotrigine 100 MG |
| Lamictal 100 mg oral tablet | Active comparator | Reference Receives: Drug: Lamotrigine 100 MG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area under the curve (AUC)
To establish bioequivalence, the calculated 90% CI for the ratio of geometric means for AUC72 and Cmax for lamotrigine should fall within 80.00%-125.00%.
Measured: blood sampling: pre-dose (0) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose
Maximal plasma concentration (Cmax)
To establish bioequivalence, the calculated 90% CI for the ratio of geometric means for AUC72 and Cmax for lamotrigine should fall within 80.00%-125.00%.
Measured: blood sampling: pre-dose (0) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jan 2024
- Study start3 Apr 2023
- Primary completion9 May 2023
- Study completion14 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FastingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Desitin Arzneimittel GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- BioPharma Services Inc.
- Responsible party
- Sponsor
- Investigators
- Janice Faulknor, MD, Principal investigator, BioPharma Services Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06199791
- Sponsor's protocol ID
- LTG-008/K
- Status last verified
- Dec 2023
- First submitted
- 12 Dec 2023
- Last updated
- 10 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Single-Dose, Randomized, Two-Way Crossover, Bioequivalence of Lamotrigine 100 mg Tablet (Desitin Arzneimittel GmbH, Germany) and Lamictal 100 mg Tablet (GlaxoSmithKline GmbH & Co. KG, Germany) in Healthy, Male Volunteers, Fasting
- ClinicalTrials.gov ID
- NCT06199791
- Acronym / sponsor ID
- LTG-008/K
- Conditions
- Fasting
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Desitin Arzneimittel GmbHIndustry (pharma, biotech, devices)
- Collaborators
- BioPharma Services Inc.
- Study start
- 3 Apr 2023 (actual)
- Primary completion
- 9 May 2023 (actual)
- Study completion
- 14 Jun 2023 (actual)
- First posted
- 10 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess the bioequivalence of lamotrigine from Lamotrigin Desitin 100 mg tablets and Lamictal 100 mg Tablet.
Detailed description
In the pivotal study bioequivalence of Lamotrigin Desitin 100 mg tablets and Lamictal 100 mg tablet in healthy, male volunteers should be proven.
The drug products were studied using a crossover design with 24 healthy, non-smoking, male volunteers being administered an oral dose of 1 × 100 mg tablet under fasting conditions.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lamotrigine 100 mg oral tablet | Experimental | Drug: Lamotrigine 100 MGTest |
| Lamictal 100 mg oral tablet | Active comparator | Drug: Lamotrigine 100 MGReference |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Healthy, non-smoking (for at least 6 months prior to first drug administration), male volunteers 18 to 65 years of age inclusive.
- BMI that was within 18.5-30.0 kg/m², inclusive.
- Healthy, according to the medical history, ECG, vital signs, laboratory results and physical examination as determined by the PI/Sub-Investigator.
- QTcB interval < 440 milliseconds for males, unless deemed otherwise by the PI/Sub- Investigator.
- Systolic blood pressure between 95-140 mmHg, inclusive, and diastolic blood pressure between 55-90 mmHg, inclusive, and heart rate between 50-100 bpm, inclusive, unless deemed otherwise by the PI/Sub-Investigator.
Key exclusion criteria (36 listed)
- Known history or presence of any clinically significant hepatic, renal/genitourinary, gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological or hematological disease or condition unless determined as not clinically significant by the PI/Sub-Investigator.
- Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g., chronic diarrhea, inflammatory bowel disease), unresolved gastrointestinal symptoms (e.g., diarrhea, vomiting), or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug experienced within 7 days prior to first study drug administration, as determined by the PI/Sub-Investigator.
- Presence of any clinically significant illness within 30 days prior to first dosing, as determined by the PI/Sub-Investigator.
- Presence of any significant physical or organ abnormality as determined by the PI/Sub-Investigator.
- A positive test result for any of the following: HIV, Hepatitis B surface antigen, Hepatitis C, drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), alcohol breath test and cotinine.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lamotrigine 100 MGAlso: Lamotrigin Desitin 100 mgtablets | Drug | Lamictal 100 mg oral tablet, Lamotrigine 100 mg oral tablet |
Primary outcome
Area under the curve (AUC)
Time frame: blood sampling: pre-dose (0) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose
To establish bioequivalence, the calculated 90% CI for the ratio of geometric means for AUC72 and Cmax for lamotrigine should fall within 80.00%-125.00%.
Maximal plasma concentration (Cmax)
Time frame: blood sampling: pre-dose (0) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose
To establish bioequivalence, the calculated 90% CI for the ratio of geometric means for AUC72 and Cmax for lamotrigine should fall within 80.00%-125.00%.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jan 2024.
- Individual participant dataSharing planned: No
Related trials for Fasting
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
RecruitingPhase 2
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
RecruitingObservational study
The Impact of Fast-Track Anesthesia on Postoperative Neurocognitive Function in Patients Undergoing Cardiac Surgery
Delirium - Postoperative, Cardiac Surgery
Not yet recruitingObservational study
Preoperative Gastric Ultrasound and Anaesthetic Management in Patients Undergoing Coronary Artery Bypass Grafting
Preoperative Fasting, Pulmonary Aspiration During Anesthetic Induction
Recruiting
Environmental Harm Menu Labels and Overall Dietary Quality
Food Choices
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Janice Faulknor, MD principal investigator
BioPharma Services Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Lamotrigine 100 MG in people with Fasting, run by Desitin Arzneimittel GmbH at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area under the curve (AUC) (time frame: blood sampling: pre-dose (0) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2024.